• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Surveillance Study of Influenza Occurrence and Immunity in a Wisconsin Cohort During the 2009 Pandemic

tetano

Editor, Senior Moderator
Open Forum Infect Dis. 2017 Feb 12;4(2):ofx023. doi: 10.1093/ofid/ofx023. eCollection 2017 Spring.
[h=1]Surveillance Study of Influenza Occurrence and Immunity in a Wisconsin Cohort During the 2009 Pandemic.[/h] Lo CY[SUP]1[/SUP], Strobl SL[SUP]2[/SUP], Dunham K[SUP]2[/SUP], Wang W[SUP]3[/SUP], Stewart L[SUP]4[/SUP], Misplon JA[SUP]1[/SUP], Garcia M[SUP]1[/SUP], Gao J[SUP]3[/SUP], Ozawa T[SUP]5[/SUP], Price GE[SUP]1[/SUP], Navidad J[SUP]6[/SUP], Gradus S[SUP]6[/SUP], Bhattacharyya S[SUP]6[/SUP], Viboud C[SUP]7[/SUP], Eichelberger MC[SUP]3[/SUP], Weiss CD[SUP]3[/SUP], Gorski J[SUP]4[/SUP], Epstein SL[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Antibody and T-cell immunity to conserved influenza virus antigens can protect animals against infection with diverse influenza strains. Although immunity against conserved antigens occurs in humans, whether such responses provide cross-protection in humans and could be harnessed as the basis for universal influenza vaccines is controversial. The 2009 pandemic provided an opportunity to investigate whether pre-existing cross-reactive immunity affected susceptibility to infection.
[h=4]METHODS:[/h] In 2009, we banked sera and peripheral blood mononuclear cells (PBMC) from blood donors, then monitored them for pandemic influenza infection (pH1N1) by polymerase chain reaction or seroconversion. Antibodies to hemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), matrix 2 (M2), and HA-pseudotypes were measured in sera. T-cell inteferon-γ enzyme-linked immunospot responses were measured in PBMC.
[h=4]RESULTS:[/h] There were 13 infections in 117 evaluable donors. Pre-existing T-cell reactivity to pH1N1 was substantial (of 153 donors tested, 146 had >100 spot-forming cells/10[SUP]6[/SUP] cells). Antibodies reactive with pH1N1 were common: anti-NP (all donors) and anti-M2 (44% of donors). Pseudotype-neutralizing antibodies to H1 were detected, but not to highly conserved HA epitopes. Unexpectedly, donors with symptomatic pH1N1 infection had sharp rises in HA pseudotype-neutralizing antibodies, not only pH1N1 but also against multiple seasonal H1s. In addition, an exploratory study of a T-cell marker (response to NP[SUB]418-426[/SUB]) identified probable infection missed by standard criteria.
[h=4]CONCLUSIONS:[/h] Although the number of infections was inadequate for conclusions about mechanisms of protection, this study documents the wide variety of pre-existing, cross-reactive, humoral and cellular immune responses to pandemic influenza virus antigens in humans. These responses can be compared with results of other studies and explored in universal influenza vaccine studies.


[h=4]KEYWORDS:[/h] conserved antigens; cross-protection; heterosubtypic immunity; influenza; pandemic.

PMID: 28730155 PMCID: PMC5510460 DOI: 10.1093/ofid/ofx023
 
Back
Top Bottom